Fenofibrate-Induced Liver Enlargement via PPARα-YAP Activation in Aging Mice

Study Background and Research Question

The liver is a central organ for metabolic regulation, xenobiotic detoxification, and maintenance of physiological homeostasis. Its unique ability to adapt in size, termed the “hepatostat,” ensures optimal functional capacity. Among the molecular regulators of liver size are nuclear receptors, including the peroxisome proliferator-activated receptor alpha (PPARα), which is especially prominent in liver tissue and governs lipid metabolism, fatty acid uptake, and β-oxidation. Previous research has established that pharmacological activation of PPARα with agonists such as fibrates induces non-adverse hepatomegaly and promotes liver regeneration in adult rodents.

Yes-associated protein (YAP), a key effector of the Hippo pathway, is also implicated in organ size control and hepatocyte proliferation. Earlier studies linked PPARα activation to YAP nuclear translocation and subsequent liver growth in adult mice. However, the influence of aging on this regulatory axis remained an open question, especially given that aged livers exhibit hallmarks of cellular senescence and diminished regenerative capacity. The primary research question addressed by the referenced study is whether Fenofibrate-induced liver enlargement and PPARα-YAP pathway activation are preserved in aging mice, or if they are attenuated due to age-associated changes in hepatic physiology.

Key Innovation from the Reference Study

The central innovation of this work is its systematic investigation of Fenofibrate’s effect on liver growth and molecular signaling in both adult and aging mice, using three validated aging models: D-galactose-induced aging, naturally aged, and senescence-accelerated mouse P8 (SAMP8) lines. By directly comparing these groups, the study isolates the variable of age and elucidates whether PPARα-YAP signaling is robust to aging-related physiological changes. This rigorously addresses a knowledge gap in the context of both basic hepatic biology and translational research using PPARα agonists in older populations.

Methods and Experimental Design Insights

The study employed a multi-model approach to aging, administering Fenofibrate to adult, D-galactose-induced aging, naturally aged, and SAMP8 mice. Doses and administration schedules were consistent with established protocols for evaluating PPARα agonist effects. Liver size was assessed via weight measurements, histological analysis focused on hepatocyte size (particularly around the central vein [CV] and portal vein [PV] regions), and proliferative activity was quantified using immunohistochemical markers for cell proliferation.

Molecular analyses included Western blotting and immunofluorescence to detect expression and subcellular localization of key proteins in the PPARα and YAP signaling axes. Levels of PPARα downstream targets, as well as proliferation-associated and YAP pathway proteins, were quantified post-treatment. The use of multiple aging models strengthens the generalizability of the findings and controls for model-specific artifacts.

Protocol Parameters

• Fenofibrate administration: Applied at doses and durations validated for robust PPARα activation in mouse models; consult referenced protocols for age-specific adjustments.
• Aging models: D-galactose-induced aging, naturally aged mice, and SAMP8 (senescence-accelerated) strains were used to capture a spectrum of aging phenotypes.
• Tissue analysis: Liver weight normalized to body weight; histology for hepatocyte hypertrophy (CV and PV regions); proliferation indices via Ki-67 or equivalent markers.
• Biochemical endpoints: Immunoblotting and immunofluorescence for PPARα, YAP, and downstream targets; nuclear/cytoplasmic protein fractionation for YAP localization.

Core Findings and Why They Matter

Key outcomes from the study include:

• Consistent Liver Enlargement Across Ages: Fenofibrate induced significant liver enlargement in aging mice, mirroring effects previously observed in adults. The degree of hepatomegaly—assessed via liver-to-body weight ratio and histological evidence of hepatocyte hypertrophy and proliferation—was equivalent between adult and aged cohorts.
• Comparable Molecular Activation: Both adult and aging mice exhibited similar upregulation of PPARα target proteins and activation of the YAP signaling pathway. Importantly, Fenofibrate treatment resulted in nuclear translocation of YAP and increased expression of proliferation-related proteins independent of age.
• Implications for Liver Physiology and Regeneration: These results suggest that aging does not diminish the hepatic response to PPARα agonist-driven YAP activation, challenging the paradigm that regenerative or growth responses are universally blunted with age. This has direct implications for the design of preclinical studies and the interpretation of data in aged animal models.

Together, the data indicate that the PPARα-YAP axis remains a viable target for modulating liver size and potentially regenerative capacity in aged organisms. The findings also provide a mechanistic rationale for the observed non-adverse hepatomegaly associated with PPARα agonist exposure in both young and old animals.

Comparison with Existing Internal Articles

No internal articles were available for direct comparison at the time of writing. However, the present study extends previous findings by specifically validating the independence of Fenofibrate-induced hepatic responses from the aging process, which can inform the design and interpretation of future research articles in lipid metabolism and cancer biology domains.

Limitations and Transferability

While the study’s use of multiple aging models strengthens its conclusions, several limitations are noted:

• The experiments were conducted exclusively in murine models, and translational relevance to human hepatic aging remains to be determined.
• The duration of Fenofibrate exposure was relatively short; longer-term studies are needed to assess the potential for adverse effects or compensatory mechanisms over time.
• While the PPARα-YAP pathway was thoroughly examined, other nuclear receptor pathways implicated in hepatic growth were not evaluated in parallel.

Researchers should also consider strain-specific and sex-dependent differences in hepatic response when extrapolating these findings to other mouse models or to human systems.

Research Support Resources

For investigators seeking to replicate or extend these findings, Fenofibrate (SKU B1943) is available as a potent and selective PPARα agonist for experimental use. According to the product information, Fenofibrate is suitable for in vitro and in vivo studies of PPARα and YAP signaling, as well as broader lipid metabolism and cancer biology research workflows. Researchers should ensure proper solubilization—Fenofibrate is insoluble in water but dissolves well in DMSO or ethanol, with warming or ultrasonic agitation recommended for optimal results. APExBIO provides detailed handling and storage recommendations for reliable experimental outcomes.